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Abstract 
Background: Asymptomatic falciparum malaria is associated with poorer cognitive performance in African school‑
children and intermittent preventive treatment of malaria improves cognitive outcomes. However, the developmental 
benefits of chemoprevention in early childhood are unknown. Early child development was evaluated as a major out‑
come in an open‑label, randomized, clinical trial of anti‑malarial chemoprevention in an area of intense, year‑round 
transmission in Uganda.
Methods: Infants were randomized to one of four treatment arms: no chemoprevention, daily trimethoprim–sul‑
famethoxazole, monthly sulfadoxine–pyrimethamine, or monthly dihydroartemisinin–piperaquine (DP), to be given 
between enrollment (4–6 mos) and 24 months of age. Number of malaria episodes, anaemia (Hb < 10) and neurode‑
velopment [Mullen Scales of Early Learning (MSEL)] were assessed at 2 years (N = 469) and at 3 years of age (N = 453); 
at enrollment 70 % were HIV‑unexposed uninfected (HUU) and 30 % were HIV‑exposed uninfected (HEU).
Results: DP was highly protective against malaria and anaemia, although trial arm was not associated with MSEL 
outcomes. Across all treatment arms, episodes of malarial illness were negatively predictive of MSEL cognitive perfor‑
mance both at 2 and 3 years of age (P = 0.02). This relationship was mediated by episodes of anaemia. This regression 
model was stronger for the HEU than for the HUU cohort. Compared to HUU, HEU was significantly poorer on MSEL 
receptive language development irrespective of malaria and anaemia (P = 0.01).
Conclusions: Malaria with anaemia and HIV exposure are significant risk factors for poor early childhood neurode‑
velopment in malaria‑endemic areas in rural Africa. Because of this, comprehensive and cost/effective intervention is 
needed for malaria prevention in very young children in these settings.
© 2016 Boivin et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The adverse effects of both cerebral malaria and severe 
malaria anaemia in preschool-age children has also been 
documented [1, 2]. However, uncomplicated malaria has 
also been associated with cognitive deficits in children. 
Vitor-Silva et  al. concluded that uncomplicated malaria 
was associated with poorer school performance in the 
Brazilian Amazon [3]. In Sri Lanka in a series of studies 
by Fernando and colleagues, poorer academic perfor-
mance and lower cognitive ability were associated with 
a higher number of malaria attacks in school children 
[4–7].
Intermittent prevention treatment (IPT) for malaria 
in schools and in communities has had cognitive and 
academic benefits in rural Gambia [8], western Kenya 
[9], Mali [10], and Zambia [11, 12], although one nega-
tive outcome was reported in a Kenyan study [13]. All 
these IPT clinical trials involved school-age children 
randomized by classrooms, schools or villages. The 
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developmental benefits of IPT, randomized to individual 
children in early childhood, are unknown.
The principal study questions are whether: (1) malaria 
illness and anaemia are related to poorer cognitive devel-
opment in preschool-age children in an area of high 
malaria transmission; and, (2) whether perinatally HIV-
exposed uninfected (HEU) children more vulnerable to 
the adverse effects of malarial illness on cognitive devel-
opment, compared to HIV-unexposed uninfected (HUU) 
children. Figure 1 depicts the principal factors in the pre-
sent study analyses (SES/Caregiving, Nutrition/Micro-
nutrient Deficiencies and Anemia, Infectious Disease/
Malaria/HIV) influencing brain development, which is 
measured by the MSEL composite score for the cognitive 




This observational study of neurodevelopmental out-
comes was embedded within a malaria chemopreven-
tion randomized controlled trial (RCT) study conducted 
at the Tororo District Hospital near the Kenyan border 
in eastern Uganda [14, 15] (ClinicalTrials.gov number 
NCT00948896). Ethical approval was obtained from the 
Uganda National Council for Science and Technology, 
the Makerere University School of Medicine Research 
and Ethics Committee, and the Biomedical Institutional 
Review Board (IRB) of Michigan State University. Writ-
ten informed consent was obtained from the principal 
caregiver (usually the biological mother) for each study 
child.
Clinical trial of chemoprevention
All children still enrolled at 2 years of age in the RCT tri-
als were eligible to be co-enrolled in the present study for 
MSEL assessment to take place at 2 and 3  years of age, 
except for those who had previously been hospitalized 
for severe malaria during the RCT study. For the RCT 
study, eligibility criteria for the HEU children included 
confirmed HIV-positive status of biological mother; con-
firmed negative HIV DNA PCR test of infant at time of 
enrolment; infant actively breastfeeding at the time of 
enrolment; residency within 30  km of the study clinic 
with no intention of moving outside the study area; 
agreement to come to the study clinic for any illness and 
to avoid medications outside the study protocol; provi-
sion of informed consent by parent/guardian; no history 
of allergy or sensitivity to any study drugs; absence of 
active medical problem requiring in-patient evaluation 
or chronic medical conditions requiring frequent atten-
tion; and absence of clinically significant electrocardio-
gram abnormalities, family history of long QT syndrome 
or current use of drugs that prolong the QT interval [15]. 
Only one eligible child was enrolled per household.
The HEU cohort mothers were on highly active antiret-
roviral therapy (HAART) during pregnancy and their 
study children were on nevirapine for 6  weeks and tri-
methoprim–sulfamethoxazole (TS) prophylaxis for the 
duration of breastfeeding, which is the standard of care 
in many African countries, including Uganda [16]. These 
HEU children were enrolled at about four to 5 months of 
age (median = 4.7 months) and monitored on a monthly 
basis. Six weeks following cessation of breastfeeding, a 
DNA PCR test was done for each participant and those 
who remained HIV uninfected were randomized to one 
of four regimens: no chemoprevention, daily TS, monthly 
sulfadoxine–pyrimethamine (SP), or monthly dihydroar-
temisinin–piperaquine (DP). For the HEU children cessa-
tion of breast feeding and subsequent randomization to 
RCT treatment arm ranged from six to 19 months of age 
(median = 9.7 months).
Eligibility criteria for the HUU children in the original 
RCT trial included the following [14]: (1) born to HIV-
uninfected mothers, (2) residency within 30  km of the 
study clinic with no intention of moving outside the study 
area, (3) agreement to come to the study clinic for any ill-
ness and to avoid medications outside the study protocol, 
(4) provision of informed consent by parent/guardian, (5) 
no history of allergy or sensitivity to any study drugs, (6) 
absence of active medical problem requiring in-patient 
evaluation or chronic medical conditions requiring fre-
quent attention, and (7) absence of clinically significant 
Fig. 1 Brain development model as evaluated in the present study. 
The developing brain is measured by the Mullen Scales of Early Learn‑
ing (MSEL) composite of the cognitive scales (visual reception, fine 
motor, receptive language, and expressive language). The measure of 
socio‑economic status (SES) includes quality of caregiving (nurture/
neglect) and physical growth (weight‑for‑age and height‑for‑age 
z scores) along with anaemia are partly the result of nutrition and 
micronutrients. Anaemia is also partly caused by the effects of infec‑
tious disease in early development, such as malaria and exposure to 
maternal HIV
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electrocardiogram (ECG) abnormalities, family history of 
long QT syndrome, and current use of drugs that prolong 
the QTc interval. Only one eligible child was enrolled per 
house.
The HUU study children in the original RCT trial were 
enrolled at 4–5  months of age (median  =  5.6  months) 
and randomized to treatment arms at 6  months of age. 
Both the HEU and HUU children were followed for all 
their health care needs including monthly routine visits. 
Chemoprevention was discontinued at 2 years of age and 
children were followed for one additional year until they 
reached 3 years of age. The primary outcomes were the 
incidence of malaria and incidence of moderate-severe 
anaemia (haemoglobin <80 gm/dL).
At enrolment in the original RCT trial, caregivers 
were given two long-lasting, insecticide-treated bed 
nets (LLINs). Anthelminthic, iron sulfate and vitamin 
A were prescribed following Integrated Management of 
Childhood Illnesses guidelines. During follow-up, chil-
dren who presented with a documented fever (tympanic 
temperature >38  °C) or a history of fever in the previ-
ous 24 h, had blood obtained by finger prick for a thick 
blood smear. Episodes of uncomplicated malaria were 
treated with standard doses of artemether–lumefantrine 
(AL). Episodes of complicated malaria or treatment fail-
ures occurring within 14  days of therapy were treated 
with quinine. Routine evaluations, including thick blood 
smears and assessment of adherence to LLINs and study 
drugs, were done monthly [15].
Study procedure
Figures  2 and 3 are CONSORT diagrams depicting the 
manner in which 186 HEU and 393 HUU children were 
randomized into 4 malaria chemoprevention treatment 
arms. The published study findings for the HUU [14] and 
HEU [15] cohorts contain the detailed methodology for 
the malaria chemoprevention RCT within which the pre-
sent neurodevelopment observational study was embed-
ded. ITNs were distributed to all study participants at 
the time of enrollment. At the time of each monthly rou-
tine visit, parents/guardians were asked whether their 
child slept under an ITN the prior evening. At the time 
of treatment allocation, parents/guardians were given a 
2 month supply of study drugs and a diary with dates for 
dosing and check-offs to indicate administration. Study 
drugs were resupplied to maintain a 2 month supply dur-
ing clinic visits. At the time of each monthly routine visit, 
parents/guardians were asked how many doses of study 
drugs were given since the last routine visit and dates of 
administration were recorded.
At 2 years of age, all HEU and HUU children not lost to 
follow-up in the RCT trials, which had not been hospital-
ized with a history of severe malaria and with caregivers 
willing to participate, were co-enrolled into our observa-
tional study for neurodevelopmental assessment with the 
MSEL. Children who had been hospitalized with severe 
malaria were excluded from the present study because of 
previous findings documenting the relationship between 
severe malaria and MSEL performance [1, 17]. As can 
be seen in Fig. 2, 143 out of 186 HEU children were co-
enrolled from the malaria chemoprevention RCT for 
MSEL testing at 2 years of age. In Fig. 3, 325 out of 393 
HUU RCT children were co-enrolled for MSEL testing at 
2 years of age. These combined totals for the RCT cohort 
samples ensured 80 % power for our MSEL neurodevel-
opmental outcomes based on prior work in Tororo [18].
Children’s neurodevelopment was assessed with the 
Mullen Scales of Early Learning (MSEL) twice; at 2 and 
again at 3  years of age. This assessment is intended for 
use in assessing children from birth to 68  months and 
provides assessment scores for the neurodevelopmental 
domains of gross motor (up to 33 months), and a com-
posite score for the cognitive scales of visual reception, 
fine motor, receptive language, and expressive language. 
This test was designed to be more easily adaptable to 
resource-limited and cross-cultural settings than the Bay-
ley Scales of Infant Development, considered to be the 
gold standard of such assessments [19]. At the same time, 
the MSEL has excellent correspondence validity with the 
Bayley scales [20]. The MSEL has been previously admin-
istered in local languages to evaluate the neurodevelop-
mental benefits of a caregiver training intervention with 
mothers of HEU children in Tororo [18]. The MSEL has 
also proven sensitive to the neurodevelopmental effects 
of severe malaria anaemia and cerebral malaria in Ugan-
dan children [1, 17].
Research assistants administering the MSEL in the pre-
sent study were all psychology Bachelor’s degree gradu-
ates of Makerere University fluent in the local languages 
who underwent 1 week of training on the test followed by 
a month of daily practice testing observation and partici-
pation. Following this training and practice period, the 
head of the assessment team at the study site observed 
the MSEL administration by the apprentice research 
assistant and approved the assistant for the assessment 
of study children contingent on good testing skills and 
satisfactory completion of an evaluation of MSEL testing 
skills as observed thereafter on a monthly basis (quality 
assurance program).
Socio-economic status (SES) was evaluated in the 
present study using a questionnaire read to the mother 
in the local language which asked a series of questions 
about the physical quality of the dwelling (materials and 
construction of floor, roof, walls, doors, windows, cook-
ing facilities, toilet facilities), availability of water and 
plumbing, availability of electricity and sources of fuel 
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for cooking/heating, material possessions such as com-
mon appliances, radio/TV, bicycle, dishes, furniture, and 
books. The mother was also asked a series of questions 
about the types of employment for pay for her and the 
father/husband or other adult household members, as 
well as domestic animals available to the household. The 
SES questionnaire asked about food security in the way 
of sources of meat, fish, poultry, agriculture and garden 
produce. Finally, the SES questionnaire for the present 
study included a set of questions about daily caregiving 
practices in the home for the study child (e.g., do you play 
with the child or read to the child most days? Does the 
child have toys to play with in the home? Are you with 
the child most of the day and who is with the child when 
you are not there?).
Measures from the SES questionnaire (Caregiving, 
Food Security and Nutrition) along with clinic-based 
measures of anemia and malaria illness were included 
along with maternal HIV status in a conceptual model 
of child neurodevelopment depicted in Fig.  1. This 
conceptual model for the present study guided the sta-
tistical analyses described below for the principal study 
measures and MSEL outcomes.
Statistical analyses
Although in the published findings of the RCT study, the 
principal outcome was malaria illness incidence per per-
son year at risk (PYAR) [14, 15], counts of malaria epi-
sodes were used as the primary exposure variable in the 
present analyses. This is because the PYAR measure was 
possibly compromised due to the aggressive treatment 
course in response to all bouts of malaria, as reported in 
the RCT study. This included the inclusion of a manda-
tory 6-week period of parasite clearance verification for 
each treatment episode for each child. However, substi-
tuting the PYAR measure for simple number of malaria 
episodes did not change any of the principal findings 
from the analyses described below.
The principal predictor in the present analyses was 
incidence of malaria, defined as the number of episodes 
205 children screened for enrollment
200 children 4-5 months of age enrolled
2 six months of age or older
2 not currently breaseeding
1 HIV status of child not confirmed by PCR
186 randomized aer cessaon of breaseeding 
and confirmed to be HIV uninfected
14 excluded prior to randomizaon
7 tested HIV posive
3 unable to locate for > 60 days
2 withdrew informed consent
1 died
1 unable to comply with protocol
46 randomized to no chemoprevenon 46 randomized to monthly SP 47 randomized to daily TS 47 randomized to monthly DP
37 tested with MSEL 24 months of age
2 prematurely withdrawn
2 died
5 hospitalized with severe malaria
4 prematurely withdrawn
2 moved out of study area
1 withdrew informed consent
1 died; 4 not enrolled in MSEL
3 hospitalized with severe malaria
31 tested with MSEL 24 months of age 36 tested with MSEL 24 months of age 39 tested with MSEL 24 months of age
4 prematurely withdrawn
2 died
1 unable to locate for > 60 days
1 unable to comply with protocol
3 hospitalized with severe malaria
2 prematurely withdrawn
1 unable to comply with protocol
1 died
2 hospitalized with severe malaria
2 not enrolled in MSEL study
1 prematurely withdrawn
1 unable to locate for > 60 days
2 lost to MSEL follow-up
2 prematurely withdrawn
1 unable to comply with protocol
1 died
1 lost to MSEL follow-up
0 prematurely withdrawn
2 lost to MSEL follow-up
5 hospitalized with severe malaria
0 prematurely withdrawn
5 lost to MSEL follow-up
33 tested with MSEL 36 months of age 26 tested with MSEL 36 months of age 29 tested with MSEL 36 months of age 34 tested with MSEL 36 months of age
Fig. 2 This is the CONSORT diagram showing the process whereby 186 perinatally HIV‑exposed and uninfected children (HEU) at 4–5 months 
of age were enrolled in a randomized controlled trial (RCT) to evaluate the effects of four different malaria chemoprevention treatment arms on 
incidence of malaria illness and levels of anaemia. At 2 years of age, these children malaria chemoprevention was discontinued and children co‑
enrolled in the present study (N = 143) were evaluated with the Mullen Scales of Early Learning (MSEL). All RCT children continued to be monitored 
for malaria illness and anaemia until 3 years of age, at which time remaining eligible children were again evaluated with the MSEL (N = 122)
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during the period the chemoprevention was given, and 
between 2 and 3 years of age after chemoprevention was 
stopped. The other exposure variable was incidence of 
anaemia during the study period: the number of incidents 
of moderate-severe anaemia (haemoglobin <10  gm/dL) 
during monthly clinic visits during the chemopreven-
tion period (up to 2 years) and during the year following 
cessation of chemoprevention (between 2 and 3 years of 
age).
Primary analyses for the first research question about 
the relation of malaria illness and anaemia with cognitive 
development was addressed using linear mixed effects 
(LME) models. The numbers of malaria and anaemia 
episodes before 2  years, and between 2 and 3  years of 
age were used as time varying covariates. Other time-
varying covariates included age, weight for age z-score 
(WAZ) and number of breastfeeding days in a time 
period. Fixed (not time-varying) covariates included trial 
arm, HIV exposure, sex, socio-economic status (SES), 
and number of observation days prior to randomiza-
tion. Height-for-age z scores (HAZ) was also added to the 
regression models (Tables 2, 3, 4, 5) but was not included 
in the final analyses because of collinearity issues with 
WAZ. Substituting HAZ for WAZ did not change any 
of our principal findings with respect to the relationship 
between malaria and MSEL outcomes with or without 
anemia.
The assumption of linearity of the relationship between 
the Mullen scores and principal exposure variables (num-
ber of malaria and anemia episodes) was evaluated using 
scatterplots. To assess the robustness of findings, sensi-
tivity analyses were performed using several cut-offs in 
the number of episodes. The results obtained from mod-
els with categorical exposure variables were not apprecia-
bly different from the results from the models with linear 
effects.
To assess the effect of exposures and the extent to 
which the effects of the number of malaria episodes were 
mediated by the anaemia, three LME models were fit.
Model 1 related the MSEL scores (one at a time) to 
time period (enrolment to 2 years, or 2–3 years), number 
of malaria episodes and other covariates described above. 
The number of anaemia episodes was not included in this 
model to assess the main effect of the malaria episodes.
Model 2 related the MSEL scores (one at a time) to 
time period (enrolment to 2 years, or 2–3 years), number 
402 children screened for enrollment
400 children 4-5 months of age enrolled
2 not willing to provide informed consent
393 randomized at 6 months of age
7 excluded prior to randomizaon for         
inability to comply with study protocol
98 randomized to no chemoprevenon 98 randomized to monthly SP 99 randomized to daily TS 98 randomized to monthly DP




2 hospitalized with severe malaria
5 withdrew consent
4 unable to locate for > 60 days
3 moved
1 unable to comply with protocol
4 hospitalized with severe malaria
2 not able to consent in MSEL
4 withdrew consent
3 moved
2 unable to locate for > 60 days
6 hospitalized with severe malaria
11 not able to consent in MSEL
4 withdrew consent
1 moved
1 unable to comply with protocol
4 hospitalized with severe malaria
81 tested with MSEL 24 months of age 82 tested with MSEL 24 months of age 77 tested with MSEL 24 months of age
85 tested with MSEL 36 months of age
2 died
1 hospitalized with severe malaria
7 more agreed to MSEL tesng 
who were missed earlier
2 died 1 hospitalized with severe malaria
1 moved
1 withdrew consent
7 more agreed to MSEL tesng who 
were missed earlier
85 tested with MSEL 36 months of age 80 tested with MSEL 36 months of age 81 tested with MSEL 36 months of age
Fig. 3 This is the CONSORT diagram showing the process whereby 393 perinatally HIV‑unexposed and uninfected children (HUU) at 5–6 months 
of age were enrolled in a randomized controlled trial (RCT) to evaluate the effects of four different malaria chemoprevention treatment arms on 
incidence of malaria illness and levels of anaemia. At 2 years of age, these children malaria chemoprevention was discontinued and children co‑
enrolled in the present study (N = 325) were evaluated with the Mullen Scales of Early Learning (MSEL). All RCT children continued to be monitored 
for malaria illness and anaemia until 3 years of age, at which time remaining eligible children were again evaluated with the MSEL along with those 
co‑enrolled between 2 and 3 years who were missed at the earlier 2‑year of age assessment (N = 331)
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of malaria episodes and other covariates. The number of 
malaria episodes was not included in this model to assess 
the main effect of the anaemia episodes.
Model 3 related the MSEL scores (one at a time) to time 
period (enrolment to 2  years, or 2–3  years), number of 
malaria episodes, number of anaemia episodes, and other 
covariates. This model assessed the effects of malaria and 
anaemia episodes over and above each other. To establish 
mediation, the effect of the number of malaria episodes 
had to be significant in Model 1. If in Model 3 the effect 
of the number of malaria episodes was no longer sig-
nificant, then complete mediation was deemed to occur 
[21–25]. If the magnitude of the effect of the number of 
malaria episodes was diminished, but was still significant 
after the inclusion of anaemia, then partial mediation had 
occurred. To gauge any effects that may differ according 
to the HIV status, Models 1–3 were run again separately 
for the HEU and HUU children. All analyses were per-
formed in SAS 9.4.
Results
The subgroup of children from the RCT cohorts (HUU 
or HEU) who were not co-enrolled in the neurodevel-
opmental observational MSEL study did not differ sta-
tistically from the present study samples on any of the 
descriptive measures in Table  1. In this table, the HEU 
children did more poorly than the HUU children on 
the MSEL receptive language and the MSEL composite 
(cognitive development) measure at 3  years of age, but 
not 2  years (P  <  0.01). HEU children had fewer bouts 
of malaria during both the chemoprevention phase 
(6 months to 2 years) (t = 5.94, P < 0.001) and post pre-
vention (2–3 years) (t = 3.78, P < 0.001). The HEU chil-
dren also had fewer bouts of anaemia before 2  years of 
age (t  =  2.35, P  =  0.02), and fewer exclusively breast-
feeding days both before and during the study (t = 7.47, 
P  <  0.001) (see Table  1). The HEU children did more 
poorly than the HUU cohort on the MSEL at 3 years of 
age (Table 1). They were significantly lower on the MSEL 
composite cognitive total (t  =  3.19, P  =  0.002), recep-
tive language (t  =  3.07, P  <  002), and visual reception 
(t = 1.97, P < 0.05). The HEU cohort also did more poorly 
than the HUU children on the MSEL expressive language 
scale at 2 years of age (t = 1.98, P < 0.05) (Table 1).
Table  2 presents the mean and standard deviation for 
the number of malaria and anaemia episodes during the 
year following chemoprevention, and also includes the 
MSEL average group performance by treatment arm at 2 
and 3 years of age. As was the case in the principal publi-
cation of RCT results for both cohorts separately [14, 15], 
DP and TS both resulted in fewer incidences of malaria 
during chemoprevention treatment compared to SP and 
the no treatment arm (F  =  12.47, P  <  0.001 for HUU; 
F = 9.83, P < 0.001 for HEU). These treatment-arm differ-
ences in malaria episodes no longer occurred after treat-
ment was stopped at 2 years of age (Table 2). Episodes of 
anaemia (haemoglobin <10  gm/dL) were also fewer for 
the DP arm during the chemoprevention phase, but only 
for the HUU cohort (F = 4.90, P = 0.002). After cessation 
of treatment, there were no longer significant differences 
among treatment arms on episodes of anaemia. There 
were no significant differences among treatment arms on 
the MSEL composite total either following chemopreven-
tion (2 years of age assessment) or a year after chemopre-
vention (at 3 years of age) (Table 2).
In Table  3 (HUU and HEU combined), malaria epi-
sodes were related to MSEL scores at 2 and 3 years of age 
when not controlling for anaemia episodes (Model 1) and 
when controlling for anaemia episodes (Model 3). This 
Table also evaluates the extent to which anaemia epi-
sodes (during and after chemoprevention) predict MSEL 
when not controlling for malaria episodes (Model 2) and 
controlling for malaria episodes (Model 3). Malaria epi-
sodes were significantly related to the MSEL composite 
score (P =  0.02), but not when controlling for anaemia 
episodes (P  =  0.13), suggesting that anaemia mediates 
this relationship. The same is true for the MSEL out-
comes of fine motor (P  <  0.01 to P  =  0.03) and recep-
tive language (P = 0.04 to P = 0.15). Similar mediational 
effects were observed when comparing the relationship 
of anaemia episodes to MSEL with and without control-
ling for malaria episodes. This was the case for composite 
cognitive ability (P = 0.01 to P = 0.10), visual reception 
(P < 0.01 to P = 0.02) and receptive language (P = 0.03 to 
P = 0.14) when exploring the malaria and anaemia epi-
sode effects (Table 3).
Trial arm was not significantly related to the Mul-
len scores over and above other variables in the models, 
notably after accounting for the numbers of malaria and/
or anaemia episodes. Over and above the malaria and 
anaemia exposure variables and other covariates, the 
HUU versus HEU status variable was only significant for 
the receptive language (favouring the unexposed). Signif-
icant predictors included age (negative association), and 
time (lower scores at 3 years of age compared to 2 years).
Table  4 presents the effects of the number of malaria 
and anaemia episodes in statistical Models 1–3 for just 
the HUU cohort. In this Table, the only MSEL score 
significantly related to malaria episodes was fine motor, 
which was mediated by anaemia episodes (P  =  0.04 to 
P  =  0.18). A similar mediational effect was observed 
when evaluating the relationship between anaemia epi-
sodes and MSEL fine motor (P = 0.03 to P = 0.14). For 
Table  5 (HEU cohort), malaria episodes were predictive 
of MSEL cognitive composite as mediated by anaemia 
episodes (P = 0.02 to P = 0.10), as well as predictive of 
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receptive language (P = 0.01 to P = 0.05). For this cohort, 
anaemia episodes only predicted MSEL visual reception 
as mediated by malaria episodes (P = 0.04 to P = 0.13).
Discussion
Within the context of a rigorous RCT study in a high-
malaria-exposure area in rural eastern Uganda, strong 
evidence is presented that repeated episodes of malaria 
illness, as mediated by anaemia, can diminish cogni-
tive development in very young children. In the present 
findings, malaria chemoprevention during early child-
hood is not directly related to child neurodevelopment. 
However, malaria episodes during and after chemopre-
vention are significantly predictive of both cognitive 
and motor development at 2 and 3  years of age. This 
study is the first to document within the rigorous con-
text of an RCT study that early uncomplicated malaria 
illness before 2 and 3 years of age can diminish cogni-
tive development in very young African children. Fur-
thermore, this relationship is at least partially mediated 
Table 1 Descriptive statistics for  the study sample for  perinatally HIV-unexposed and  uninfected (HUU) and  exposed 
and uninfected (HEU)
* P < 0.05; ** P < 0.01; *** P < 0.001
a z scores for this physical growth measure were based on World Health Organization 2013 global norms








Mean (SD) Mean (SD)
Age at first MSEL neurodevelopmental assessment (years) 2.20 (0.16) 2.17 (0.16)
Age at second MSEL neurodevelopmental assessment (years) 3.02 (0.06) 3.05 (0.14)
Weight‑for‑age z‑score at first assessmenta −0.10 (1.09)* −0.38 (1.03)
Weight‑for‑age z‑score at second assessmenta −1.25 (1.05) −1.24 (0.98)
Days of observation prior to randomization 22.13 (15.51) 204.39 (107.27)
Days breastfeeding before 2 years of age 634.48 (95.79)*** 284.82 (106.76)
Days breastfeeding between 2 and 3 years of age 12.92 (31.42)*** 0 (0)
Number of malaria episodes before 2 years of age 7.38 (4.95) 4.27 (4.21)***
Number of malaria episodes between 2 and 3 years 7.93 (3.93) 6.27 (4.19)*
Number of anaemia episodes (Hb < 10 gm/dL) before 2 years 7.10 (5.37) 5.56 (4.97)*
Number of anaemia episodes (Hb < 10 gm/dL) between 2 and 3 years 0.56 (0.76) 0.70 (0.80)
MSEL gross motor (raw score) at 2 years 23.5 (3.28) 23.4 (3.16)
MSEL gross motor (raw score) at 3 years 27.5 (3.14) 27.3 (3.13)
MSEL visual reception (T score) at 2 years 35.0 (9.22) 34.0 (9.65)
MSEL visual reception (T score) at 3 years 31.8 (10.06) 29.6 (10.52)
MSEL fine motor (T score) at 2 years 33.8 (9.24) 33.5 (9.38)
MSEL fine motor (T score) at 3 years 36.5 (7.85) 34.9 (8.68)
MSEL receptive language (T score) at 2 years 41.4 (10.4) 40.9 (10.38)
MSEL receptive language (T score) at 3 years 42.0 (7.71)** 39.4 (8.45)
MSEL expressive language (T score) at 2 years 36.1 (7.91)* 34.5 (7.57)
MSEL expressive language (T score) at 3 years 37.4 (10.77) 37.3 (11.43)
MSEL composite cognitive total (standard score) at 2 years 75.0 (12.04) 73.6 (12.15)
MSEL composite cognitive total (standard score) at 3 years 75.6 (11.94)** 72.0 (10.14)
Sex N (%) N (%)
Male 174 (53) 63 (52)
Female 152 (47) 59 (48)
Treatment arm from 6 months to 3 years of age N (%) N (%)
No chemoprevention (placebo) 85 (25) 33 (27)
Monthly sulfadoxine–pyrimethamine (SP) 85 (26) 26 (21)
Daily trimethoprim–sulfamethoxazole (TS) 80 (24) 29 (24)
Monthly dihydroartemisinin–piperaquine (DP) 81 (25) 34 (28)
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by anaemia. However, another form of analysis that 
might have been used to better understand the mediat-
ing effects of anemia is structural equation modeling. 
Future work could employ this statistical method as 
well.
HIV exposure resulted in lower MSEL scores on 
composite cognitive performance at 3  years of age, 
especially receptive and expressive language. MSEL dif-
ferences were observed at 2 years of age only at the 0.05 
significance level on Expressive Language (P  <  0.05). 
These differences may have been due to differing levels of 
sensitivity of these scales to the developmental effects of 
HIV-exposure in this setting, depending on which devel-
opmental domains blossom most at a given year of age. 
For example, MSEL language development differences 
for HEU children compared to HUU children in rural 
Uganda has been previously observed in the pre-school 
age years [26].
















RCT trial arm—HUU cohort
No chemopreven‑
tion (placebo)












4.76 (4.39)*** 8.00 (3.83) 5.24 (4.41)** 0.49 (0.66) 75.78 (12.24) 77.04 (11.78)
RCT trial arm—HEU cohort
No chemopreven‑
tion (placebo)












2.74 (3.15)*** 5.68 (3.77) 4.88 (3.62) 0.68 (0.80) 74.45 (12.19) 69.21 (10.43)
Table 3 Malaria and anaemia episodes effects on the Mullen Scales of Early Learning (MSEL) scores for both cohorts com-
bined (HUU and HEU)
* P < 0.05; ** P < 0.01
MSEL outcome scores Malaria episodes effects Anaemia episodes effects
Model 1: not controlling 
for anaemia episodes
Model 3: controlling  
for anaemia episodes
Model 2: not controlling 
for malaria episodes
Model 3: controlling 
for malaria episodes
Coef (SE) P value Coef (SE) P value Coef (SE) P value Coef (SE) P value
Composite −0.22 (0.09) 0.02* −0.16 (0.10) 0.13 −0.23 (0.09) 0.01** −0.17 (0.10) 0.10
Visual reception −0.12 (0.08) 0.12 −0.04 (0.09) 0.63 −0.23 (0.08) <0.01** −0.21 (0.09) 0.02*
Fine motor −0.19 (0.07) <0.01** −0.17 (0.08) 0.03* −0.14 (0.07) 0.07 −0.07 (0.08) 0.42
Receptive language −0.16 (0.08) 0.04* −0.12 (0.08) 0.15 −0.17 (0.08) 0.03* −0.12 (0.09) 0.14
Expressive language −0.08 (0.08) 0.39 −0.05 (0.08) 0.54 −0.08 (0.08) 0.36 −0.05 (0.09) 0.56
Gross motor T score −0.01 (0.03) 0.74 0.01 (0.03) 0.86 −0.03 (0.03) 0.19 −0.03 (0.03) 0.21
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It should also be noted that the relationship between 
episodes of malaria illness and MSEL composite cognitive 
and receptive language performance for the HEU cohort 
was more robust than for the HUU cohort in the present 
study (comparing Tables 4, 5), when the MSEL outcomes 
were considered at 3  years of age. Cognitive develop-
ment risk from malaria and anaemia seems to be greater 
in HEU children, especially as they enter into the critical 
preschool-age years at 3 years of age. However, the clini-
cal significance of the statistically significant relationships 
observed in the present study between malaria illness 
and MSEL developmental outcomes is uncertain. This 
is because true Uganda-based norms are missing for the 
MSEL, and only American-based norms are available for 
standardizing performance on the basis of age and gender.
Despite this more robust relationship, the overall num-
ber of episodes of malaria illness and anaemia during and 
after chemoprevention was lower for the HEU than for 
the HUU cohorts (Table 1). This is likely due to the fact 
that in the RCT study within which this observational 
study was embedded, the HEU children were main-
tained on TS while nursing, rather than being weaned 
and randomized to the chemoprevention treatment arms 
at 6 months of age as were the HUU children. Both TS 
and DP chemoprevention significantly reduced the num-
ber of malaria episodes compared to the SP and placebo 
treatment arms [14, 15, 27].
Although a significant relationship was observed 
between episodes of malaria illness and neurodevelop-
mental outcomes in the present study findings, signifi-
cant neurodevelopmental differences were not observed 
among chemoprevention treatment arms, either during 
or after the treatment phase. This might be partly due to 
questionable adherence to the treatment arm regimens 
on the part of the mothers of the children, as witnessed 
by the results of monitoring of DP blood levels in the 
RCT trial [14, 15]. Chemoprevention treatment adher-
ence was mostly monitored by self-report on the part 
of the mothers during their monthly clinic visits. Such 
adherence issues would also pertain to the use of pro-
phylactic antibiotics and micronutrient supplements pro-
vided for participants during the study period.
Finally, socio-economic and educational sta-
tus can impact on both the reliable use of malaria 
Table 4 Malaria and anaemia episodes effects on the Mullen Scales of Early Learning (MSEL) scores for the HUU cohort
* P < 0.05; ** P < 0.01
MSEL outcome scores Malaria episodes effects Anaemia episodes effects
Model 1: not controlling 
for anaemia episodes
Model 3: controlling 
for anaemia episodes
Model 2: not controlling 
for malaria episodes
Model 3: controlling 
for malaria episodes
Coef (SE) P value Coef (SE) P value Coef (SE) P value Coef (SE) P value
Composite cognitive total −0.13 (0.11) 0.26 −0.08 (0.12) 0.54 −0.17 (0.11) 0.13 −0.14 (0.12) 0.25
Visual reception −0.05 (0.09) 0.58 0.01 (0.10) 0.88 −0.17 (0.10) 0.08 −0.18 (0.11) 0.10
Fine motor −0.16 (0.08) 0.04* −0.12 (0.08) 0.18 −0.19 (0.09) 0.03* −0.14 (0.10) 0.14
Receptive language −0.06 (0.09) 0.48 −0.03 (0.09) 0.74 −0.11 (0.09) 0.20 −0.10 (0.10) 0.30
Expressive language −0.04 (0.09) 0.61 −0.04 (0.10) 0.67 −0.04 (0.09) 0.65 −0.02 (0.11) 0.82
Gross motor T score 0.01 (0.03) 0.71 0.02 (0.03) 0.48 −0.02 (0.03) 0.43 −0.03 (0.03) 0.32
Table 5 Malaria and anaemia episodes effects on the Mullen Scales of Early Learning (MSEL) scores for the HEU cohort
* P < 0.05; ** P < 0.01
Mullen outcome scores Malaria episodes effects Anaemia episodes effects
Model 1: not controlling 
for anaemia episodes
Model 3: controlling 
for anaemia episodes
Model 2: not controlling 
for malaria episodes
Model 3: controlling 
for malaria episodes
Coef (SE) P value Coef (SE) P value Coef (SE) P value Coef (SE) P value
Composite −0.41 (0.18) 0.02* −0.32 (0.19) 0.10 −0.32 (0.17) 0.06 −0.19 (0.19) 0.32
Visual reception −0.26 (0.16) 0.10 −0.14 (0.18) 0.41 −0.35 (0.17) 0.04* −0.28 (0.18) 0.13
Fine motor −0.22 (0.14) 0.13 −0.27 (0.16) 0.09 0.00 (0.14) 0.99 0.12 (0.16) 0.46
Receptive language −0.40 (0.15) 0.01** −0.34 (0.17) 0.05* −0.30 (0.16) 0.07 −0.15 (0.18) 0.41
Expressive language −0.16 (0.15) 0.28 −0.12 (0.17) 0.47 −0.15 (0.16) 0.33 −0.10 (0.17) 0.57
Gross motor T score −0.06 (0.05) 0.21 −0.04 (0.05) 0.42 −0.06 (0.05) 0.23 −0.04 (0.05) 0.46
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chemoprevention medications and quality of housing in 
terms of night-time exposure of study children to mos-
quitoes [28]. In the previous study of HEU children in 
Tororo, SES, maternal educational level, nutritional 
quality, housing quality, and maternal depression were 
all related to child neurodevelopment independent of 
malaria episodes per se [18]. Duration of breast feeding 
is related to morbidity for both the HEU and HUU chil-
dren in the study cohorts [29]. These important factors 
related to child development may not have been equally 
distributed across chemoprevention treatment arms in 
this observational study within the larger RCT study.
The present study findings support other studies with 
school-age children that conclude that repeated episodes 
of malaria are associated with poor cognitive scores and 
low academic performance [9, 30]. Even asymptomatic 
positive malaria parasitaemia led to poorer cognitive 
performance among school-age children at the Tororo 
study site [31]. Unfortunately, the relationship between 
asymptomatic positive parasitaemia and MSEL measures 
of neurodevelopment could not be evaluated in the pre-
sent study. Whenever children developed a fever and had 
a positive blood smear the day before or at their monthly 
clinic visit, they were treated with AL and monitored for 
parasite clearance following treatment.
Because convenience sampling was used to enroll the 
original HEU cohort of 200 and the HUU cohort of 400 
infants at 4–5 mo of age from the Tororo District Hospi-
tal Maternal and Child Health Clinic their birth records 
were incomplete. Therefore, premature and low-birth 
weight children could not be excluded and this may have 
led to developmental delays that could compromise the 
sensitivity of the MSEL outcomes to the effects of malaria 
illness frequency and anaemia in the present sam-
ples. HEU children in this study area are at significantly 
greater risk for premature birth and complications, and 
shorter duration of breast feeding [32]. These risk fac-
tors can lead to developmental delays at measured by the 
MSEL [26]. Maternal depression for mothers with HIV 
can also affect MSEL outcomes for HEU children, and 
this was not measured for mothers in the present study 
[33]. This could also obscure the relationship between 
malaria or anaemia and MSEL outcomes in the present 
analyses and serve as a study limitation.
Beyond LLIN distribution programmes, little has been 
done for very young children in Africa to protect them 
against malaria. In rural households in Tororo District 
which have been provided with LLINs, children can 
still have as high as 310 infectious bites per year with a 
malaria-positive parasite prevalence rate of 28.7  % [28]. 
In the present study cohorts, where LLINs and prompt 
effective treatment were provided, the risk of compli-
cated malaria and anaemia was extremely low. However, 
incidence of malaria illness was still high with the present 
standard of care (SP) (malaria illnesses  >  seven times/
year) and increased as soon as more effective chemopre-
vention (DP and TS) was discontinued. This suggests that 
more is needed in early malaria prevention than simply 
improved LLIN distribution. This includes preventing 
malaria exposure for mothers during pregnancy, espe-
cially mothers with HIV [34].
In the longer term, malaria vaccines may have an 
important role in protecting this important section of 
the community from malaria. Regardless of the control 
approach selected, it is important that a comprehensive 
and aggressive community-wide approach to controlling 
malaria be incorporated into every public health pro-
gramme in malaria-endemic regions, as part of the ongo-
ing effort to enhance the health of African school-age 
children [30].
Conclusions
Early bouts of malaria illness can diminish cognitive 
development in very young children. These effects of 
malaria illness on cognition are partly mediated by anae-
mia, and cognitive development risk from malaria and 
anaemia seems to be greater in HEU children. This is the 
case even with children and caregivers who are provided 
with free and effective medical care and nutritional sup-
port in the first years of life. The high level of malaria 
transmission and the host of other risk factors in such 
low-resource environments can still overwhelm such 
medical and nutritional support, even when provided in 
a conscientious manner in such settings.
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